Skip to main content
placeholder image

Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2018

Citation


  • Yoshino, T., Obermannova, R., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T. -E., . . . Tabernero, J. (2018). Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.. Journal of Clinical Oncology, 36(4_suppl), 622. doi:10.1200/jco.2018.36.4_suppl.622

Web Of Science Accession Number


Start Page


  • 622

End Page


  • 622

Volume


  • 36

Issue


  • 4_suppl

Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2018

Citation


  • Yoshino, T., Obermannova, R., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T. -E., . . . Tabernero, J. (2018). Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.. Journal of Clinical Oncology, 36(4_suppl), 622. doi:10.1200/jco.2018.36.4_suppl.622

Web Of Science Accession Number


Start Page


  • 622

End Page


  • 622

Volume


  • 36

Issue


  • 4_suppl